​

Funding Round

Series B - Locus Biosciences

Series B - Locus Biosciences

Investment Firm

Overview

Locus Biosciences develops CRISPR-engineered precision antibacterial platform designed to revolutionize the treatment of bacterial disease.

Announced Date

May 18, 2022

Funding Type

Series B

Highlights

Location

United States, North America

Social

Investor Lead

Artis Ventures (AV)

Artis Ventures (AV)

Artis Ventures (AV) is a convertible_note and early_stage_venture and late_stage_venture and seed and venture firm.

Participant Investors

4

Investor Name
Participant InvestorDiscovery Innovations
Participant InvestorViking Global Investors
Participant InvestorJohnson & Johnson Robotics and Digital Solutions
Participant InvestorArtis Ventures (AV)

Round Details and Background

Locus Biosciences raised $35000000 on 2022-05-18 in Series B

Locus Biosciences develops CRISPR-engineered precision antibacterial platform designed to revolutionize the treatment of bacterial disease.

Company Funding History

10

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Feb 14, 2022
Venture Round - Locus Biosciences
-10.5M
Apr 15, 2016
Seed Round - Locus Biosciences
-1.3M
Dec 06, 2016
Debt Financing - Locus Biosciences
-350.0K
May 18, 2022
Series B - Locus Biosciences
5-35.0M

Recent Activity

There is no recent news or activity for this profile.